Richardson, Paul
Aggarwal, Saurabh
Topaloglu, Ozlem
Villa, Kathleen F.
Corbacioglu, Selim
Article History
Received: 21 August 2018
Revised: 20 December 2018
Accepted: 20 January 2019
First Online: 25 February 2019
Change Date: 26 March 2019
Change Type: Update
Change Date: 1 April 2019
Change Type: Correction
Change Details: The original version of this article included some minor typesetting errors in Table 1 – a corrected version of which is provided in the linked correction article and has been corrected in this article – and one error in text, which has been corrected in this article. Furthermore, the article was erroneously published with the copyright holders as ‘Springer Nature Limited’, however, since the article is Open Access, the copyright holders should in fact be ‘The Author(s)’. This has now been corrected in this article.
Change Details: The original version of this article included some minor typesetting errors in Table 1–a corrected version of which is provided in this correction article and has been corrected in the original article–and one error in text, which has been corrected in the original article. Furthermore, the article was erroneously published with the copyright holders as ‘Springer Nature Limited’, however, since the article is Open Access, the copyright holders should in fact be ‘The Author(s)’. This has also been corrected in the original article.
Compliance with ethical standards
:
: Paul G. Richardson has served on advisory committees and as a consultant, and received research funding from Jazz Pharmaceuticals. Saurabh Aggarwal and Ozlem Topaloglu are employees of Novel Health Strategies, which received funding from Jazz Pharmaceuticals for this analysis. Kathleen Villa is an employee of Jazz Pharmaceuticals and holds stock and/or stock options in Jazz Pharmaceuticals plc. Selim Corbacioglu has served as a consultant to and received honoraria from Gentium/Jazz Pharmaceuticals.